Vanguard Group Inc. Lowers Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Vanguard Group Inc. cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 0.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,153,957 shares of the biopharmaceutical company’s stock after selling 25,414 shares during the quarter. Vanguard Group Inc. owned 8.96% of ACADIA Pharmaceuticals worth $404,762,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ACAD. Royal Bank of Canada grew its position in ACADIA Pharmaceuticals by 74.4% in the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock valued at $1,338,000 after buying an additional 34,352 shares during the last quarter. AQR Capital Management LLC grew its position in ACADIA Pharmaceuticals by 3.8% in the 1st quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock valued at $1,124,000 after buying an additional 2,492 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in ACADIA Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 6,303 shares during the last quarter. Empowered Funds LLC purchased a new position in ACADIA Pharmaceuticals in the 1st quarter valued at $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in ACADIA Pharmaceuticals by 14.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 31,931 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Strong launch for DAYBUE: management said DAYBUE generated roughly $101M in Q1 and DAYBUE STIX is now broadly available in the U.S., supporting near-term commercial growth. Business Wire: Q1 Results & DAYBUE Remarks
• Positive Sentiment: Revenue grew ~9.7% year-over-year to $268.1M, indicating underlying demand trends despite the quarter missing consensus. Q1 Slide Deck / Press Release
• Neutral Sentiment: Company reaffirmed 2026 revenue guidance in the release (citing $1.2B–$1.3B range), which provides guidance stability but leaves investors focused on execution against that target. Yahoo Finance: Press Release
• Neutral Sentiment: Analyst coverage remains mixed-to-positive overall (average moderate-buy, average price target ~$31), so longer-term sentiment is supportive if execution continues. MarketBeat Analyst Snapshot
• Negative Sentiment: Q1 EPS missed expectations: $0.02 vs. consensus $0.04, and revenue missed estimates (~$268.1M vs. ~$280.3M consensus) — the EPS miss and lower-than-expected top line are the main drivers of the share weakness. Yahoo Finance: Earnings Miss
• Negative Sentiment: Recent insider selling: two executives disclosed modest sales (James Kihara and EVP Mark Schneyer), which can amplify short-term selling pressure even if transactions may be routine. InsiderTrades: Insider Sales
• Negative Sentiment: Conference call/transcript highlighted commercial and R&D progress but offered limited new pipeline catalysts to offset the quarterly miss immediately. Seeking Alpha: Q1 Call Transcript

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the completion of the transaction, the executive vice president owned 66,145 shares of the company’s stock, valued at approximately $1,441,299.55. The trade was a 5.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer J. Rhodes sold 6,950 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares of the company’s stock, valued at $177,898.42. The trade was a 47.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,527 shares of company stock valued at $350,917 in the last 90 days. 26.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ACAD. Citizens Jmp lifted their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 3rd. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Royal Bank Of Canada decreased their target price on shares of ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Finally, Weiss Ratings lowered shares of ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.21.

ACADIA Pharmaceuticals Stock Down 3.9%

NASDAQ:ACAD opened at $21.48 on Thursday. The company has a market capitalization of $3.68 billion, a PE ratio of 9.38, a price-to-earnings-growth ratio of 23.31 and a beta of 0.86. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.45 and a 52-week high of $28.35. The stock has a fifty day simple moving average of $22.10 and a 200-day simple moving average of $23.89.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.11 EPS. As a group, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.45 earnings per share for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.